Our strategy is to develop herpesvirus-based vaccine platforms for use in animals to protect them against infectious disease. These diseases include both economically important agricultural diseases, such as bovine tuberculosis in cattle and African Swine Fever Virus in pigs, and zoonotic diseases that are transferred from animals to humans, such as Lassa fever. Most emerging infections, especially those with high pandemic potential in humans emerge from domestic and wildlife animal populations. Due to the ability to test animal vaccines in their intended host, and the relative speed at which animal compared to human vaccines are approved for use, direct vaccination of animals rather humans is becoming accepted as an approach to protect humans against some emerging zoonotic pathogens.